Literature DB >> 2164590

Polypeptide composition of rotavirus empty capsids and their possible use as a subunit vaccine.

H Brüssow1, A Bruttin, S Marc-Martin.   

Abstract

Two types of empty capsid particles that differed with respect to the presence of the two outer shell proteins were isolated from MA-104 cells infected with bovine rotavirus V1005. Three previously uncharacterized polypeptides, I, II, and III, migrating between VP2 and VP6, were detected in empty capsids but not in single- and double-shelled rotavirus particles. Peptide mapping revealed that all three proteins were related to VP2. Polypeptides I, II, and III could be generated by in vitro trypsin digestion of empty capsids not exposed to trypsin in the infection medium. Labeled polypeptides appeared in empty capsids before they were detected in intracellular single- or double-shelled rotavirus particles. Empty capsids were also observed in MA-104 cells infected with bovine rotaviruses UK and NCDV, simian rotavirus SA11, and human rotavirus KU. VP7-containing empty capsid is the minimal subunit vaccine for cows; we failed to induce a substantial neutralizing antibody increase with VP7 purified under denaturating or nondenaturating conditions or with synthetic peptides corresponding to two regions of VP7.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164590      PMCID: PMC249656          DOI: 10.1128/JVI.64.8.3635-3642.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Trypsin enhancement of rotavirus infectivity: mechanism of enhancement.

Authors:  S M Clark; J R Roth; M L Clark; B B Barnett; R S Spendlove
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

3.  Antigenic relationships between rotaviruses from different species as studied by neutralization and immunofluorescence.

Authors:  K Sato; Y Inaba; Y Miura; S Tokuhisa; M Matumoto
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

4.  Preparation and characterization of antisera to electrophoretically purified SA11 virus polypeptides.

Authors:  J W Bastardo; J L McKimm-Breschkin; S Sonza; L D Mercer; I H Holmes
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

5.  Purification and characterization of bovine rotavirus cores.

Authors:  P Bican; J Cohen; A Charpilienne; R Scherrer
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

6.  Identification of a neutralization-specific antigen of a calf rotavirus.

Authors:  H M Killen; N J Dimmock
Journal:  J Gen Virol       Date:  1982-10       Impact factor: 3.891

7.  Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralizing antibodies.

Authors:  M E Andrew; D B Boyle; B E Coupar; P L Whitfeld; G W Both; A R Bellamy
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

8.  Passive immunity in calf rotavirus infections: maternal vaccination increases and prolongs immunoglobulin G1 antibody secretion in milk.

Authors:  D R Snodgrass; K J Fahey; P W Wells; I Campbell; A Whitelaw
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

9.  Routine isolation and cultivation of bovine rotaviruses in cell culture.

Authors:  P A Bachmann; R G Hess
Journal:  Am J Vet Res       Date:  1981-12       Impact factor: 1.156

10.  Rapid diagnosis of rotavirus infection by direct detection of viral nucleic acid in silver-stained polyacrylamide gels.

Authors:  A J Herring; N F Inglis; C K Ojeh; D R Snodgrass; J D Menzies
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

View more
  8 in total

1.  Three-dimensional structural analysis of recombinant rotavirus-like particles with intact and amino-terminal-deleted VP2: implications for the architecture of the VP2 capsid layer.

Authors:  J A Lawton; C Q Zeng; S K Mukherjee; J Cohen; M K Estes; B V Prasad
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Glycosphingolipid binding specificities of rotavirus: identification of a sialic acid-binding epitope.

Authors:  C Delorme; H Brüssow; J Sidoti; N Roche; K A Karlsson; J R Neeser; S Teneberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Immunization with baculovirus-expressed recombinant rotavirus proteins VP1, VP4, VP6, and VP7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice.

Authors:  T Dharakul; M Labbe; J Cohen; A R Bellamy; J E Street; E R Mackow; L Fiore; L Rott; H B Greenberg
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Monoclonal anti-idiotype induces antibodies against bovine Q17 rotavirus.

Authors:  E M Cornaglia; Y M Elazhary; B R Brodeur; B G Talbot
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Expression of rotavirus VP2 produces empty corelike particles.

Authors:  M Labbé; A Charpilienne; S E Crawford; M K Estes; J Cohen
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.

Authors:  Khuzwayo C Jere; Hester G O'Neill; A Christiaan Potgieter; Alberdina A van Dijk
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines.

Authors:  F M Fernandez; M E Conner; D C Hodgins; A V Parwani; P R Nielsen; S E Crawford; M K Estes; L J Saif
Journal:  Vaccine       Date:  1998-03       Impact factor: 3.641

8.  Isotype-specific antibody responses to rotavirus and virus proteins in cows inoculated with subunit vaccines composed of recombinant SA11 rotavirus core-like particles (CLP) or virus-like particles (VLP).

Authors:  F M Fernandez; M E Conner; A V Parwani; D Todhunter; K L Smith; S E Crawford; M K Estes; L J Saif
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.